JP2025183283A5 - - Google Patents

Info

Publication number
JP2025183283A5
JP2025183283A5 JP2025146941A JP2025146941A JP2025183283A5 JP 2025183283 A5 JP2025183283 A5 JP 2025183283A5 JP 2025146941 A JP2025146941 A JP 2025146941A JP 2025146941 A JP2025146941 A JP 2025146941A JP 2025183283 A5 JP2025183283 A5 JP 2025183283A5
Authority
JP
Japan
Prior art keywords
composition
dihydroquinoline
quinoline
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025146941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025183283A (ja
Filing date
Publication date
Priority claimed from JP2023013779A external-priority patent/JP7387926B2/ja
Application filed filed Critical
Publication of JP2025183283A publication Critical patent/JP2025183283A/ja
Publication of JP2025183283A5 publication Critical patent/JP2025183283A5/ja
Pending legal-status Critical Current

Links

JP2025146941A 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス Pending JP2025183283A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22
JP2023013779A JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023138310A Division JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Publications (2)

Publication Number Publication Date
JP2025183283A JP2025183283A (ja) 2025-12-16
JP2025183283A5 true JP2025183283A5 (https=) 2026-02-10

Family

ID=85382684

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023013779A Active JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A Active JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2025146941A Pending JP2025183283A (ja) 2022-02-01 2025-09-04 選択的エストロゲン受容体分解剤の調製のためのプロセス

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2023013779A Active JP7387926B2 (ja) 2022-02-01 2023-02-01 選択的エストロゲン受容体分解剤の調製のためのプロセス
JP2023138310A Active JP7805336B2 (ja) 2022-02-01 2023-08-28 選択的エストロゲン受容体分解剤の調製のためのプロセス

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TW202523669A (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100849559B1 (ko) 2004-01-22 2008-07-31 일라이 릴리 앤드 캄파니 혈관운동 증상의 치료를 위한 선택적 에스트로겐 수용체조절제
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
AU2012257802A1 (en) 2011-05-17 2013-10-31 F. Hoffmann-La Roche Ag Inhibitors of Bruton's tyrosine kinase
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
CN112424205B (zh) 2018-07-12 2023-10-31 伊莱利利公司 选择性的雌激素受体降解剂
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR20220046586A (ko) 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
CA3169679A1 (en) 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2021191378A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Similar Documents

Publication Publication Date Title
JP2025183283A5 (https=)
JP2024516371A5 (https=)
JP2020169171A5 (https=)
JP2022509091A5 (https=)
JP2024538705A5 (https=)
JP2021530451A5 (https=)
JP2024512154A5 (https=)
CN113906013A (zh) 吡啶氮氧化合物及其制备方法和用途
RU2017134551A (ru) Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств
JP2023002516A5 (https=)
CA2506082A1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary disease
JP2023082086A5 (https=)
JP2006514012A5 (https=)
JP2013541502A5 (https=)
JP2011502174A5 (https=)
BR112022022281A2 (pt) Misturas e composições compreendendo 5-fluoro-4-imino-3-metil- 1-tosil-3,4-dihidropirimidin-2-ona e métodos de uso das mesmas
JP2017522304A5 (https=)
JP2025142197A5 (https=)
JP2010505869A5 (https=)
KR101853718B1 (ko) 코지산 유도체 제조 방법
JP2022520410A5 (https=)
JP2022541772A5 (https=)
CZ294365B6 (cs) Deriváty kolchicinu, způsob výroby a farmaceutický prostředek
AR029399A1 (es) Compuestos derivados del benzofurano, una composicion farmaceutica, y el uso de dichos compuestos para la manufactura de un medicamento o una sal farmaceuticamente aceptable para el tratamiento de arritmias cardiacas
WO2009007895A4 (en) A compound showing anti-inflammatory activity and antiviral activity, pharmaceutical compositions comprising the same, a process for obtaining the same and use of the same in the treatment of epidemic keratoconjunctivites and herpetic stromal keratis